Nonspecificity of monoclonal antibody tordji-22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis
✍ Scribed by Doughty, Alison L. ;Painter, Dorothy M. ;McCaughan, Geoffrey W.
- Publisher
- Wiley (John Wiley & Sons)
- Year
- 1999
- Tongue
- English
- Weight
- 264 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1074-3022
No coin nor oath required. For personal study only.
✦ Synopsis
Detection of hepatitis C virus (HCV) antigens in liver tissue provides important diagnostic and pathological information. Limited studies have been performed on tissue taken after liver transplantation for HCV. In this study, serial post-liver transplantation biopsy tissue from patients with recurrent HCV was tested, with particular interest in patients showing severe cholestatic hepatitis. HCV-related antigens were detected using the commercial monoclonal antibody, Tordji-22. Initial results were promising, showing intense positive staining, especially in areas of hepatocyte ballooning. HCV-negative donor tissue was con-sistently negative by staining. However, as a final control for the level of tissue damage, HCV negative posttransplantation biopsy tissue showing hepatocyte ballooning was examined. These tissues also showed positive staining. All attempts to eliminate this nonspecific interaction failed. In conclusion, Tordji-22 was associated with nonspecificity in this posttransplantation population, and care is warranted when using this monoclonal antibody.
📜 SIMILAR VOLUMES
## Abstract The relative value of an anti‐hepatitis C virus (HCV) serological assay and reverse transcriptase‐nested polymerase chain reaction assays (RT‐PCR) were investigated for the constant 5′ putative noncoding region of HCV for the diagnosis of HCV‐associated chronic liver diseases in India.
In natural history studies of hepatitis C virus (HCV) infection, women have a lower risk of disease progression to cirrhosis. Whether female sex influences outcomes of HCV in the posttransplantation setting is unknown. All patients transplanted for HCV-related liver disease from 2002-2007 at five Un